arrow
A

Antonio Salar

hospital universitario virgen de la arrixaca
H指数:43
被引数:6,671

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tumor Mutational Burden as a Prognostic Biomarker in Follicular Lymphoma

肿瘤突变负荷作为滤泡性淋巴瘤的预后生物标志物

Cancers
IF4.4
2026-02-260
OAAI
Real-world effectiveness and safety of zanubrutinib in Spanish patients with relapsed/refractory marginal zone lymphoma

zanubrutinib在西班牙复发性/难治性边缘区淋巴瘤患者中的真实世界有效性与安全性

2026-01-010
OA
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial

塔fasitamab、lenalidomide和阿利霉素在复发或难治性滤泡性淋巴瘤(inMIND)中的研究:一项全球性、III期、随机对照试验

2025-12-050
PRE
Laboratory Prognostic Index (LAB-PI) in diffuse large B-cell lymphoma: a single blood analysis predicts outcomes as good as IPI, NCCN-IPI, and GELTAMO-IPI☆

弥漫大B细胞淋巴瘤中的实验室预后指数(LAB-PI):单一血液分析预测结果与IPI、NCCN-IPI和GELTAMO-IPI相当☆

2025-11-250
OAAI
Genomic characterization of clonal B-cell lymphocytosis of marginal zone origin with MYC rearrangements

MYC易位的边缘区起源克隆性B细胞淋巴细胞增生的基因组特征

2025-07-290
PRE
Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab inpatients with relapsed/refractory large B-cell lymphoma

地塞米松与 glofitamab 预治疗中替代糖皮质激素方案相比,可降低大B细胞淋巴瘤复发/难治性患者细胞因子释放综合征的发生频率和强度。

2024-11-280
OA
Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)

Tafasitamab 联合 Lenalidomide 和 Rituximab 治疗复发或难治性滤泡性淋巴瘤:来自一项 3 期研究(inMIND)的结果

BLOOD
IF23.1
2024-11-253
PRE
The 66th ASH Annual Meeting Abstracts POSTER ABSTRACTS

第66届ASH年会摘要 海报摘要

BLOOD
IF23.1
2024-11-050
PRE
Generation and External Validation of a Histologic Transformation Risk Model for Patients with Follicular Lymphoma
2024-07-012
PRE
Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy

免疫化疗一线治疗滤泡性淋巴瘤4项预后指标的评价

2023-04-256
OAAI
Multi-hit TET2 mutations as a differential molecular signature of oligomonocytic and overt chronic myelomonocytic leukemia

多命中TET2突变作为寡单核细胞和明显的慢性粒细胞单核细胞白血病的差异分子特征

LEUKEMIA
IF13.4
2022-10-2210
PRE
Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups

Car-t细胞时代难治性侵袭性b细胞淋巴瘤患者的最佳治疗选择: 来自GELTAMO/GETH西班牙小组的真实世界证据

2022-07-1229
OAAI